Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
Approval Alert | Ponatinib/Chemotherapy in Ph+ Acute Lymphoblastic Leukemia
Advertisement
Advertisement
Trending on CancerNetwork
1
Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL
2
Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer
3
Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma
4
Optimizing the Timing of Genetic Testing in Advanced Ovarian Cancer
5
